Suppr超能文献

胆道癌的靶向药物治疗:最新进展与未来展望

Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.

作者信息

Hopfner Michael, Schuppan Detlef, Scherubl Hans

出版信息

World J Gastroenterol. 2008 Dec 14;14(46):7021-32. doi: 10.3748/wjg.14.7021.

Abstract

The limited efficacy of cytotoxic therapy for advanced biliary tract and gallbladder cancers emphasizes the need for novel and more effective medical treatment options. A better understanding of the specific biological features of these neoplasms led to the development of new targeted therapies, which take the abundant expression of several growth factors and cognate tyrosine kinase receptors into account. This review will briefly summarize the status and future perspectives of antiangiogenic and growth factor receptor-based pharmacological approaches for the treatment of biliary tract and gallbladder cancers. In view of multiple novel targeted approaches, the rationale for innovative therapies, such as combinations of growth factor (receptor)-targeting agents with cytotoxic drugs or with other novel anticancer drugs will be highlighted.

摘要

细胞毒性疗法对晚期胆管癌和胆囊癌的疗效有限,这凸显了对新型且更有效治疗方案的需求。对这些肿瘤特定生物学特征的深入了解促使了新的靶向疗法的开发,这些疗法考虑到了多种生长因子和相关酪氨酸激酶受体的大量表达。本综述将简要总结基于抗血管生成和生长因子受体的药物治疗方法在胆管癌和胆囊癌治疗中的现状及未来前景。鉴于多种新型靶向方法,将重点介绍创新疗法的理论依据,例如将生长因子(受体)靶向药物与细胞毒性药物或其他新型抗癌药物联合使用。

相似文献

1
Targeted medical therapy of biliary tract cancer: recent advances and future perspectives.
World J Gastroenterol. 2008 Dec 14;14(46):7021-32. doi: 10.3748/wjg.14.7021.
3
Targeting Angiogenesis in Biliary Tract Cancers: An Open Option.
Int J Mol Sci. 2017 Feb 15;18(2):418. doi: 10.3390/ijms18020418.
4
Targeted therapy in biliary tract cancer: 2009 update.
Future Oncol. 2009 Dec;5(10):1675-84. doi: 10.2217/fon.09.130.
5
Targeted therapy for biliary tract cancers.
J Hepatobiliary Pancreat Sci. 2012 Jul;19(4):326-36. doi: 10.1007/s00534-011-0496-0.
6
Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
Curr Opin Oncol. 2006 May;18(3):247-52. doi: 10.1097/01.cco.0000219253.53091.fb.
7
Molecular targeted therapies: Ready for "prime time" in biliary tract cancer.
J Hepatol. 2020 Jul;73(1):170-185. doi: 10.1016/j.jhep.2020.03.007. Epub 2020 Mar 12.
8
Angiogenesis in biliary tract cancer: targeting and therapeutic potential.
Expert Opin Investig Drugs. 2021 Apr;30(4):411-418. doi: 10.1080/13543784.2021.1881479. Epub 2021 Mar 28.
9
Continuum of care for advanced biliary tract cancers.
Clin Res Hepatol Gastroenterol. 2020 Nov;44(6):810-824. doi: 10.1016/j.clinre.2020.05.009. Epub 2020 Jun 22.
10
Targeted therapy for biliary-tract cancer.
Lancet Oncol. 2010 Jan;11(1):5-6. doi: 10.1016/S1470-2045(09)70370-5.

引用本文的文献

本文引用的文献

2
The role of angiogenesis inhibitors in prostate cancer.
Cancer J. 2008 Jan-Feb;14(1):20-5. doi: 10.1097/PPO.0b013e318161c014.
3
AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.
World J Gastroenterol. 2007 Dec 28;13(48):6470-7. doi: 10.3748/wjg.v13.i48.6470.
4
Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma.
Br J Cancer. 2008 Jan 29;98(2):418-25. doi: 10.1038/sj.bjc.6604129. Epub 2007 Dec 18.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验